- US-listed companies
- LIGAND PHARMACEUTICALS INC
- Income statement
LIGAND PHARMACEUTICALS INCLGND
Market cap
$3.9B
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 30 | 31 | 49 | 65 | 72 | 109 | 141 | 251 | 120 | 186 | 277 | 196 | 131 | 167 |
| Revenue growth (%) | - | |||||||||||||
| Cost of revenue | 5 | 4 | 6 | 9 | 6 | 6 | 5 | 6 | 11 | 30 | 62 | 53 | 11 | 11 |
| Research & development | 10 | 11 | 9 | 12 | 13 | 21 | 27 | 28 | 56 | 59 | 69 | 36 | 25 | 21 |
| Operating margin (%) | ||||||||||||||
| Operating income | -1 | 1 | 15 | 20 | 27 | 44 | 68 | 164 | 807 | 26 | 79 | 3 | 12 | -23 |
| Income before tax | -3 | -4 | 9 | 11 | 35 | 8 | 57 | 173 | 797 | -11 | 47 | 36 | 64 | 3 |
| Pretax margin (%) | -9.8 | -12.3 | 18.8 | 17.5 | 49.1 | 7.3 | 40.6 | 68.9 | 662.3 | -5.7 | 17.1 | 18.4 | 48.5 | 1.5 |
| Provision for income taxes | -13 | - | 0 | 0 | -220 | 10 | 45 | 30 | 167 | -8 | -10 | 41 | 10 | 7 |
| Effective tax rate (%) | - | |||||||||||||
| Net income | 10 | -1 | 11 | 12 | 257 | -2 | 13 | 143 | 629 | -3 | 57 | -33 | 52 | -4 |
| Net income margin (%) | ||||||||||||||
| Earnings per share | - | - | 0.56 | 0.59 | 13 | -0.08 | 0.6 | 6.77 | 33.13 | -0.18 | 3.44 | -1.98 | 3.02 | -0.22 |
| Diluted EPS | - | - | 0.55 | 0.56 | 12.12 | -0.08 | 0.53 | 5.96 | 31.85 | -0.18 | 3.31 | -1.98 | 2.94 | -0.22 |
| EBITDA | ||||||||||||||
| EBITDA margin (%) |